1. Ahmad, I, Rathore, FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020;77:8-12.
Google Scholar | Crossref | Medline2. Bonilla, FA, Barlan, I, Chapel, H, et al. International consensus document (ICON): Common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38-59.
Google Scholar | Crossref | Medline3. Fadakar, N, Ghaemmaghami, S, Masoompour, SM, et al. A first case of acute cerebellitis associated with coronavirus disease (COVID-19): A case report and literature review. Cerebellum. 2020;19:911-914.
Google Scholar | Crossref | Medline4. Abrams, RMC, Lehrer, H, Yeung, A, et al. A case of elsberg syndrome in the setting of asymptomatic SARS-CoV-2 infection. J Clin Neuromuscul Dis. 2021;22:228-231.
Google Scholar | Crossref | Medline5. Abrams, RMC, Safavi, F, Tuhrim, S, Navis, A, Steinberger, J, Shin, SC. MRI negative myelopathy post mild SARS-CoV-2 infection: vasculopathy or inflammatory myelitis? J Neurovirol. 2021;27:650-655.
Google Scholar | Crossref | Medline6. Asadi-Pooya, AA, Simani, L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci 2020;413:116832.
Google Scholar | Crossref | Medline7. Cohen, B, Rubinstein, R, Gans, MD, Deng, L, Rubinstein, A, Eisenberg, R. COVID-19 infection in 10 common variable immunodeficiency patients in New York city. J Allergy Clin Immunol Pract. 2021;9:504-507.e1.
Google Scholar | Crossref | Medline8. Tay, MZ, Poh, CM, Rénia, L, MacAry, PA, Ng, LFP. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363-374.
Google Scholar | Crossref | Medline9. Baral, PK, Nuruzzaman, M, Uddin, MS, Ferdous, M, Chowdhury, IH, Smrity, SZ. Severe acute respiratory syndrome coronavirus 2 invasion in the central nervous system: A host-virus deadlock. Acta Virol. 2021;65:115-126.
Google Scholar | Crossref | Medline10. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
Google Scholar | Crossref | Medline11. Kumar, A, Prasoon, P, Kumari, C, et al. SARS-CoV-2-specific virulence factors in COVID-19. J Med Virol. 2021;93:1343-1350.
Google Scholar | Crossref | Medline12. Velikova, TV, Kotsev, SV, Georgiev, DS, Batselova, HM. Immunological aspects of COVID-19: What do we know? World J Biol Chem. 2020;11:14-29.
Google Scholar | Crossref | Medline13. Avouac, J, Drumez, E, Hachulla, E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol. 2021;3:e419-e426.
Google Scholar | Crossref | Medline14. Ho, HE, Mathew, S, Peluso, MJ, Cunningham-Rundles, C. Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. J Allergy Clin Immunol Pract. 2021;9:490-493.e2.
Google Scholar | Crossref | Medline15. Stokes, EK, Zambrano, LD, Anderson, KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. MMWR. 2020;69:759-765.
Google Scholar | Crossref | Medline16. Cunningham, JL, Virhammar, J, Rönnberg, B, et al. Anti-SARS-CoV2 antibody responses in serum and cerebrospinal fluid of COVID-19 patients with neurological symptoms. J Infect Dis 2021;jiab153.
Google Scholar | Crossref | Medline17. Lee, MH, Perl, DP, Nair, G, et al. Microvascular injury in the brains of patients with Covid-19. N Engl J Med. 2021;384:481-483.
Google Scholar | Crossref | Medline18. Solomon, IH, Normandin, E, Bhattacharyya, S, et al. Neuropathological features of Covid-19. N Engl J Med. 2020;383:989-992.
Google Scholar | Crossref | Medline19. Matschke, J, Lütgehetmann, M, Hagel, C, et al. Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurol. 2020;19:919-929.
Google Scholar | Crossref | Medline20. Ludlow, M, Kortekaas, J, Herden, C, et al. Neurotropic virus infections as the cause of immediate and delayed neuropathology. Acta Neuropathol. 2016;131:159-184.
Google Scholar | Crossref | Medline21. Xi, Y . Convalescent plasma therapy for COVID-19: a tried-and-true old strategy? Signal Transduct Target Ther. 2020;5:203.
Google Scholar | Crossref | Medline23. Simonovich, VA, Burgos Pratx, LD, Scibona, P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619-629.
Google Scholar | Crossref | Medline24. Van Damme, KFA, Tavernier, S, Van Roy, N, et al. Case report: Convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19. Front Immunol. 2020;11:596761.
Google Scholar | Crossref | Medline25. Jin, H, Reed, JC, Liu, STH, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract. 2020;8:3594-3596.e3.
Google Scholar | Crossref | Medline